Motor and Non-Motor features of Parkinson's disease - A Review of clinical and experimental Studies

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 4, 2012, Pages 439-449

  Lima, Marcelo M S ^a   Martins, Emerson F ^b   Delattre, Ana Márcia ^a   Proença, Mariana B ^a   Mori, Marco A ^a   Carabelli, Bruno ^a   Ferraz, Anete C ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Animal models; Dopamine; Neurodegeneration; Nigrostriatal pathway; Tyrosine hydroxylase

Indexed keywords

ANXIETY DISORDER; AUTONOMIC GANGLION; BALANCE DISORDER; BRADYKINESIA; BRAIN STEM; CAUDATE NUCLEUS; CLINICAL FEATURE; COGNITIVE DEFECT; CONSTIPATION; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; DYSPHAGIA; ESOPHAGUS DISEASE; FOREBRAIN; HUMAN; LIMB WEAKNESS; LIMBIC CORTEX; MOTOR CORTEX; MUSCLE FATIGUE; MUSCLE RIGIDITY; NEOCORTEX; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PREMOTOR CORTEX; PUTAMEN; REVIEW; SLEEP DISORDER; SPINAL CORD; TREMOR; VOLUNTARY MOVEMENT;

EID: 84862571593     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712800792893     Document Type: Review

References (147)

1. Lang, A.E.; Lozano, A.M. Parkinson's disease. First of two parts. N. Engl. J. Med., 1998, 339, 1044-1053.
2. Lang, A.E.; Lozano, A.M. Parkinson's disease. Second of two parts. N. Engl. J. Med., 1998, 339, 1130-1143.
3. Pulst, S.-M. Genetics of Movement disorders. Acad. Press, 2003, San Diego, California, USA.
4. Schapira, A.H.V.; Bezard, E.; Brotchie, J. Novel pharmacological targets for the treatment of Parkinson's disease. Nat. Rev. Drug Discov., 2006, 5, 845-854.
5. Dauer, W.; Przedborski, S. Parkinson's disease: mechanisms and models. Neuron, 2003, 39, 889-909.
6. Barnham, J.K.; Masters, A.B.; Bush, A. Neurodegenerative disease and oxidative stress. Nat. Rev. Drug Discov., 2004, 3, 205-214.
7. Teismann, P.; Tieu, K.; Choi, D.K.; Wu, D.C.; Naini, A.; Hunot, S.; Vila, M.; Jackson-Lewis, V.; Przedborski, S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. USA, 2003, 100, 5473-5478.
8. Double, K.L.; Reyes, S.; Werry, E.L.; Halliday, G.M. Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions? Prog. Neurobiol., 2010, 92, 316-329.
9. Braak, H.; Ghebremedhin, E.; Rub, U.; Bratzke, H.; Del Tredici, K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res., 2004, 318, 121-134.
10. Braak, H.; De Vos, R.A.; Jansen, E.N.; Bratzke, H.; Braak, E. Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. Prog. Brain Res., 1998, 117, 267-285.
11. Braak, H.; Rub, U.; Gai, W.P.; Del Tredici, K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm., 2003, 110, 517-536.
12. Braak, H.; Del Tredici, K.; Rub, U.; De Vos, R.A.; Jansen Steur, E.N.; Braak, E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging. 2003, 24, 197-211.
13. Schmechel, D. Translational research in Alzheimer's disease and Parkinson's disease. Neurotoxicology, 2006, 27, 1157-1157.
14. Papapetropoulos, S.; Shehadeh, L.; Mccorquodale, D. Optimizing human post-mortem brain tissue gene expression profiling in Parkinson's disease and other neuro degenerative Fishing to disorders: From target translational breakthroughs. J. Neurosci. Res., 2007, 85, 3013-3024.
15. Chan, C.S.; Gertler, T.S.; Surmeier, D.J. Calcium homeostasis, selective vulnerability and Parkinson's disease. Trends Neurosci., 2009, 32, 249-256.
16. Meredith, G.E.; Totterdell, S.; Potashkin, J.A.; Surmeier, J. Modeling PD pathogenesis in mice: Advantages of a chronic MPTP protocol. Parkinsonism Relat. Disord., 2008, 14, S112-S115.
17. Allen, N.E.; Sherrington, C.; Paul, S.S.; Canning, C.G. Balance and falls in parkinson's disease: a meta-analysis of the effect of exercise and motor training. Mov. Disord., 2011, 26, 1605-1615.
18. Daubner, S.C.; Le, T.; Wang, S. Tyrosine hydroxylase and regulation of dopamine synthesis. Arch. Biochem. Biophys., 2011, 508, 1-12.
19. Friedrich, C.; Reichmann, H.; Ziemssen, T. Treatment of autonomic dysfunction in patients with extrapyramidal disorders. Fortschr. Neurol. Psychiatr., 2010, 78, 445-455.
20. Perretti, A.; De Rosa, A.; Marcantonio, L.; Iodice, V.; Estraneo, A.; Manganelli, F.; Garavaglia, B.; Filla, A.; Santoro, L.; De Michele, G. Neurophysiological evaluation of motor corticospinal pathways by TMS in idiopathic early-onset Parkinson's disease. Clin. Neurophysiol., 2011, 122, 546-549.
21. Longoni, G.; Agosta, F.; Kostic, V.S.; Stojkovic, T.; Pagani, E.; Stosic-Opincal, T.; Filippi, M. MRI measurements of brainstem structures in patients with Richardson's syndrome, progressive supranuclear palsy-parkinsonism, and Parkinson's disease. Mov. Disord., 2011, 26, 247-255.
22. Pombero, A.; Bueno, C.; Saglietti, L.; Rodenas, M.; Guimera, J.; Bulfone, A.; Martinez, S. Pallial origin of basal forebrain cholinergic neurons in the nucleus basalis of Meynert and horizontal limb of the diagonal band nucleus. Development, 2011, 138, 4315-4326.
23. Drapier, D.; Drapier, S.; Sauleau, P.; Haegelen, C.; Raoul, S.; Biseul, I.; Peron, J.; Lallement, F.; Rivier, I.; Reymann, J.M.; Edan, G.; Verin, M.; Millet, B. Does subthalamic nucleus stimulation induce apathy in Parkinson's disease? J. Neurol., 2006, 253, 1083-1091.
24. Knaryan, V.H.; Samantaray, S.; Le Gal, C.; Ray, S.K.; Banik, N.L. Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies. J. Neurochem., 2011, 118, 326-338.
25. Hirsch, E.C. Mechanism and consequences of nerve cell death in Parkinson's disease. J. Neural Transm. Suppl., 1999, 56, 127-137.
26. Deumens, R.; Blokland, A.; Prickaerts, J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol., 2002, 175, 303-317.
27. Betarbet, R.; Canet-Aviles, R.M.; Sherer, T.B.; Mastroberardino, P.G.; Mclendon, C.; Kim, J.H.; Lund, S.; Na, H.M.; Taylor, G.; Bence, N.F.; Kopito, R.; Seo, B.B.; Yagi, T.; Yagi, A.; Klinefelter, G.; Cookson, M.R.; Greenamyre, J.T. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol. Dis., 2006, 22, 404-420.
28. Stocchi, F.; Barbato, L.; Nordera, G.; Berardelli, A.; Ruggieri, S. Sleep disorders in Parkinson's disease. J. Neurol., 1998, 245(Suppl 1), S15-S18.
29. Hallet, M. Bradykinesia: Why do parkinson's patients have it and what trouble does it cause? Mov. Disord., 2011, 26, 1579-1581.
30. Christakos, C.N.; Erimaki, S.; Anagnostou, E.; Anastasopoulos, D. Tremor-related motor unit firing in Parkinson's disease: implications for tremor genesis. J. Physiol. Lond., 2009, 587, 4811-4827.
31. Friedman, J.H.; Abrantes, A.; Sweet, L.H. Fatigue in Parkinson's disease. Expert Opin. Pharmacother., 2011, 12, 1999-2007.
32. Roland, K.P.; Jakobi, J.M.; Powell, C.; Jones, G.R. Factors related to functional independence in females with Parkinson's disease: A systematic review. Maturitas, 2011, 69, 304-311.
33. Santello, M.; Muratori, L.; Gordon, A.M. Control of multidigit grasping in Parkinson's disease: effect of object property predictability. Exp. Neurol., 2004, 187, 517-528.
34. Salenius, S.; Avikainen, S.; Kaakkola, S.; Hari, R.; Brown, P. Defective cortical drive to muscle in Parkinson's disease and its improvement with levodopa. Brain, 2002, 125, 491-500.
35. Possin, K.L.; Filoteo, J.V.; Song, D.D.; Salmon, D.P. Spatial and object working memory deficits in Parkinson's disease are due to impairment in different underlying processes. Neuropsychology, 2008, 22, 585-595.
36. Kempf, F.; Kuhn, A.A.; Kupsch, A.; Brucke, C.; Weise, L.; Schneider, G.H.; Brown, P. Premovement activities in the subthalamic area of patients with Parkinson's disease and their dependence on task. Eur. J. Neurosci., 2007, 25, 3137-3145.
37. Nambu, A. A new approach to understand the pathophysiology of Parkinson's disease. J. Neurol., 2005, 252, IV1-IV4.
38. Den Oudsten, B.L.; Van Heck, G.L.; De Vries, J. Quality of life and related concepts in Parkinson's disease: a systematic review. Mov. Disord., 2007, 22, 1528-1537.
39. Prediger, R.D.; Matheus, F.C.; Schwarzbold, M.L.; Lima, M.M.; Vital, M.A. Anxiety in Parkinson's disease: a critical review of experimental and clinical studies. Neuropharmacology, 2012, 62, 115-124.
40. Chaudhuri, K.R.; Healy, D.G.; Schapira, A.H. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol., 2006, 5, 235-245.
41. Pintor, L.; Bailles, E.; Valldeoriola, F.; Tolosa, E.; Marti, M.J.; De Pablo, J. Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode. Gener. Hosp. Psychiatry, 2006, 28, 59-64.
42. Tadaiesky, M.T.; Dombrowski, P.A.; Figueiredo, C.P.; Cargnin-Ferreira, E.; Da Cunha, C.; Takahashi, R.N. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience, 2008, 156, 830-840.
43. Santiago, R.M.; Barbieiro, J.; Lima, M.M.; Dombrowski, P.A.; Andreatini, R.; Vital, M.A. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2010, 34, 1104-1114.
44. Castano, A.; Herrera, A.J.; Cano, J.; Machado, A. The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J Neurochem. 2002, 81, 150-157.
45. Dutta, G.; Zhang, P.; Liu, B. The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam. Clin. Pharmacol., 2008, 22, 453-464.
46. Mori, A.; Ohashi, S.; Nakai, M.; Moriizumi, T.; Mitsumoto, Y. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice. Neurosci. Res., 2005, 51, 265-274.
47. Zhu, X.R.; Maskri, L.; Herold, C.; Bader, V.; Stichel, C.C.; Gunturkun, O.; Lubbert, H. Non-motor behavioural impairments in parkin-deficient mice. Eur. J. Neurosci., 2007, 26, 1902-1911.
48. George, S.; Van Den Buuse, M.; San Mok, S.; Masters, C.L.; Li, Q.X.; Culvenor, J.G. Alpha-synuclein transgenic mice exhibit reduced anxiety-like behaviour. Exp. Neurol., 2008, 210, 788-792.
49. Taylor, T.N.; Caudle, W.M.; Shepherd, K.R.; Noorian, A.; Jackson, C.R.; Iuvone, P.M.; Weinshenker, D.; Greene, J.G.; Miller, G.W. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J. Neurosci., 2009, 29, 8103-8113.
50. Nilsson, F.M.; Kessing, L.V.; Bolwig, T.G. Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study. Acta Psychiatr. Scand., 2001, 104, 380-386.
51. Schuurman, A.G.; Van Den Akker, M.; Ensinck, K.T.; Metsemakers, J.F.; Knottnerus, J.A.; Leentjens, A.F.; Buntinx, F. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology, 2002, 58, 1501-1504.
52. Remy, P.; Doder, M.; Lees, A.; Turjanski, N.; Brooks, D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain, 2005, 128, 1314-1322.
53. Weintraub, D.; Moberg, P.J.; Duda, J.E.; Katz, I.R.; Stern, M.B. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J. Am. Geriatr. Soc., 2004, 52, 784-788.
54. Winter, C.; Von Rumohr, A.; Mundt, A.; Petrus, D.; Klein, J.; Lee, T.; Morgenstern, R.; Kupsch, A.; Juckel, G. Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. Behav. Brain Res., 2007, 184, 133-141.
55. Navailles, S.; Benazzouz, A.; Bioulac, B.; Gross, C.; De Deurwaerdere, P. High-frequency stimulation of the subthalamic nucleus and L-3,4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease. J. Neurosci., 2010, 30, 2356-2364.
56. Schrag, A.; Jahanshahi, M.; Quinn, N. What contributes to quality of life in patients with Parkinson's disease? J. Neurol. Neurosurg. Psychiatry, 2000, 69, 308-312.
57. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov. Disord., 2002, 17, 60-67.
58. Karlsen, K.H.; Larsen, J.P.; Tandberg, E.; Maeland, J.G. Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 1999, 66, 431-435.
59. Hobson, P.; Holden, A.; Meara, J. Measuring the impact of Parkinson's disease with the Parkinson's disease quality of life questionnaire. Age Ageing, 1999, 28, 341-346.
60. Behari, M.; Srivastava, A.K.; Pandey, R.M. Quality of life in patients with Parkinson's disease. Parkinsonism Relat. Disord., 2005, 11, 221-226.
61. Mayeux, R.; Williams, J.B.; Stern, Y.; Cote, L. Depression and Parkinson's disease. Adv. Neurol., 1984, 40, 241-250.
62. Mayeux, R. Depression in the patient with Parkinson's disease. J. Clin. Psychiatry, 1990, 51(Suppl), 20-23; discussion 24-25.
63. Frisina, P.G.; Haroutunian, V.; Libow, L.S. The neuropathological basis for depression in Parkinson's disease. Parkinsonism Relat. Disord., 2009, 15, 144-148.
64. Schrag, A. Psychiatric aspects of Parkinson's disease--an update. J. Neurol., 2004, 251, 795-804.
65. Dremencov, E.; Newman, M.E.; Kinor, N.; Blatman-Jan, G.; Schindler, C.J.; Overstreet, D.H.; Yadid, G. Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment. Neuropharmacology, 2005, 48, 34-42.
66. Menza, M.; Dobkin, R.D.; Marin, H.; Mark, M.H.; Gara, M.; Buyske, S.; Bienfait, K.; Dicke, A. The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease. Mov. Disord., 2009, 24, 1325-1332.
67. Hauser, R.A. Levodopa: past, present, and future. Eur. Neurol., 2009, 62, 1-8.
68. Gumpert, J.; Sharpe, D.; Curzon, G. Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa. J. Neurol. Sci., 1973, 19, 1-12.
69. Jenner, P.; Sheehy, M.; Marsden, C.D. Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease. Br. J. Clin. Pharmacol., 1983, 15(Suppl 2), 277S-289S.
70. Kish, S.J.; Tong, J.; Hornykiewicz, O.; Rajput, A.; Chang, L.J.; Guttman, M.; Furukawa, Y. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain, 2008, 131, 120-131.
71. Borah, A.; Mohanakumar, K.P. Long-term L-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats. Cell Mol. Neurobiol., 2007, 27, 985-996.
72. Reksidler, A.B.; Lima, M.M.S.; Dombrowski, P.; Barnabé, G.F.; Andersen, M.L.; Tufik, S.; Vital, M.A.B.F. Distinct Effects of Intranigral L-DOPA Infusion in the MPTP Rat Model of Parkinson's Disease. J. Neural Transm. Suppl., 2009, 73, 259-268.
73. Navailles, S.; Bioulac, B.; Gross, C.; De Deurwaerdere, P. Chronic L-DOPA therapy alters central serotonergic function and L-DOPAinduced dopamine release in a region-dependent manner in a rat model of Parkinson's disease. Neurobiol. Dis., 2011, 41, 585-590.
74. Reichmann, H.; Schneider, C.; Lohle, M. Non-motor features of Parkinson's disease: depression and dementia. Parkinsonism Relat. Disord., 2009, 15(Suppl 3), S87-S92.
75. Emre, M. Dementia associated with Parkinson's disease. Lancet Neurol., 2003, 2, 229-237.
76. Aarsland, D.; Kurz, M.W. The epidemiology of dementia associated with Parkinson disease. J. Neurol. Sci., 2010, 289, 18-22.
77. Jellinger, K.A. Interaction between alpha-synuclein and tau in Parkinson's disease comment on Wills et al., elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp. Neurol. 2010, 227, 13-18.
78. Colloby, S.J.; Williams, E.D.; Burn, D.J.; Lloyd, J.J.; Mckeith, I.G.; O'brien, J.T. Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT. Eur. J. Nucl. Med. Mol. Imaging, 2005, 32, 1176-1185.
79. Willis, A.W.; Sterling, C.; Racette, B.A. Conjugal Parkinsonism and Parkinson disease: a case series with environmental risk factor analysis. Parkinsonism Relat. Disord., 2010, 16, 163-166.
80. Song, I.U.; Kim, J.S.; Jeong, D.S.; Song, H.J.; Lee, K.S. Early neuropsychological detection and the characteristics of Parkinson's disease associated with mild dementia. Parkinsonism Relat. Disord., 2008, 14, 558-562.
81. Lewis, S.J.; Slabosz, A.; Robbins, T.W.; Barker, R.A.; Owen, A.M. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease. Neuropsychologia, 2005, 43, 823-832.
82. Metzler-Baddeley, C. A review of cognitive impairments in dementia with Lewy bodies relative to Alzheimer's disease and Parkinson's disease with dementia. Cortex, 2007, 43, 583-600.
83. Kehagia, A.A.; Barker, R.A.; Robbins, T.W. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol., 2011, 9, 1200-1213.
84. Alves, G.; Larsen, J.P.; Emre, M.; Wentzel-Larsen, T.; Aarsland, D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov. Disord., 2006, 21, 1123-1130.
85. Burn, D.J.; Mckeith, I.G. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease. Mov. Disord., 2003, 18(Suppl 6), S72-S79.
86. Janvin, C.C.; Aarsland, D.; Larsen, J.P. Cognitive predictors of dementia in Parkinson's disease: a community-based, 4-year longitudinal study. J. Geriatr. Psychiatry Neurol., 2005, 18, 149-154.
87. Janvin, C.C.; Larsen, J.P.; Aarsland, D.; Hugdahl, K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov. Disord., 2006, 21, 1343-1349.
88. Beyer, M.K.; Janvin, C.C.; Larsen, J.P.; Aarsland, D. A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J. Neurol. Neurosurg. Psychiatry, 2007, 78, 254-259.
89. Williams-Gray, C.H.; Foltynie, T.; Brayne, C.E.; Robbins, T.W.; Barker, R.A. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain, 2007, 130, 1787-1798.
90. Lima, M.M.S.; Reksidler, A.B.; Vital, M.A. The neurobiology of the substantia nigra pars compacta: from motor to sleep regulation. J. Neural Transm. Suppl., 2009, 73, 135-145.
91. Lima, M.M.S.; Reksidler, A.B.; Vital, M.A.B.F. The dopaminergic dilema: Sleep or wake? implications in Parkinson's disease. Biosci. Hyp., 2008, 1, 9-13.
92. Tandberg, E.; Larsen, J.P.; Karlsen, K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov. Disord., 1998, 13, 895-899.
93. Truong, D.D.; Bhidayasiri, R.; Wolters, E. Management of nonmotor symptoms in advanced Parkinson disease. J. Neurol. Sci., 2008, 266, 216-228.
94. Hogl, B.; Rothdach, A.; Wetter, T.C.; Trenkwalder, C. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease. Neuropsychopharmacology, 2003, 28, 1866-1870.
95. Pace-Schott, E.F.; Hobson, J.A. The neurobiology of sleep: genetics, cellular physiology and subcortical networks. Nat. Rev. Neurosci., 2002, 3, 591-605.
96. Arnulf, I. Sleep and wakefulness disturbances in Parkinson's disease. J. Neural Transm. Suppl., 2006, 357-360.
97. Arnulf, I.; Konofal, E.; Merino-Andreu, M.; Houeto, J.L.; Mesnage, V.; Welter, M.L.; Lacomblez, L.; Golmard, J.L.; Derenne, J.P.; Agid, Y. Parkinson's disease and sleepiness: an integral part of PD. Neurology, 2002, 58, 1019-1024.
98. Larsen, J.P.; Tandberg, E. Sleep disorders in patients with Parkinson's disease: epidemiology and management. CNS Drugs, 2001, 15, 267-275.
99. Dzirasa, K.; Ribeiro, S.; Costa, R.; Santos, L.M.; Lin, S.C.; Grosmark, A.; Sotnikova, T.D.; Gainetdinov, R.R.; Caron, M.G.; Nicolelis, M.A. Dopaminergic control of sleep-wake states. J. Neurosci., 2006, 26, 10577-10589.
100. Mena-Segovia, J.; Giordano, M. Striatal dopaminergic stimulation produces c-Fos expression in the PPT and an increase in wakefulness. Brain Res., 2003, 986, 30-38.
101. Chaudhuri, K.R.; Naidu, Y. Early Parkinson's disease and nonmotor issues. J. Neurol., 2008, 255(Suppl 5), 33-38.
102. Anderson, G.; Noorian, A.R.; Taylor, G.; Anitha, M.; Bernhard, D.; Srinivasan, S.; Greene, J.G. Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease. Exp. Neurol., 2007, 207, 4-12.
103. Abbott, R.D.; Petrovitch, H.; White, L.R.; Masaki, K.H.; Tanner, C.M.; Curb, J.D.; Grandinetti, A.; Blanchette, P.L.; Popper, J.S.; Ross, G.W. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology, 2001, 57, 456-462.
104. Huang, X.F.; Tork, I.; Paxinos, G. Dorsal motor nucleus of the vagus nerve: a cyto- and chemoarchitectonic study in the human. J. Comp. Neurol., 1993, 330, 158-182.
105. Hopkins, D.A.; Bieger, D.; Devente, J.; Steinbusch, W.M. Vagal efferent projections: viscerotopy, neurochemistry and effects of vagotomy. Prog. Brain Res., 1996, 107, 79-96.
106. Kaneoke, Y.; Koike, Y.; Sakurai, N.; Washimi, Y.; Hirayama, M.; Hoshiyama, M.; Takahashi, A. Gastrointestinal dysfunction in Parkinson's disease detected by electrogastroenterography. J. Auton. Nerv. Syst., 1995, 50, 275-281.
107. Saha, A.R.; Hill, J.; Utton, M.A.; Asuni, A.A.; Ackerley, S.; Grierson, A.J.; Miller, C.C.; Davies, A.M.; Buchman, V.L.; Anderton, B.H.; Hanger, D.P. Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons. J. Cell Sci., 2004, 117, 1017-1024.
108. Benarroch, E.E.; Schmeichel, A.M.; Sandroni, P.; Low, P.A.; Parisi, J.E. Involvement of vagal autonomic nuclei in multiple system atrophy and Lewy body disease. Neurology, 2006, 66, 378-383.
109. Edwards, L.L.; Quigley, E.M.; Harned, R.K.; Hofman, R.; Pfeiffer, R.F. Defecatory function in Parkinson's disease: response to apomorphine. Ann. Neurol., 1993, 33, 490-493.
110. Chaudhuri, K.R.; Schapira, A.H. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol., 2009, 8, 464-474.
111. Honig, H.; Antonini, A.; Martinez-Martin, P.; Forgacs, I.; Faye, G.C.; Fox, T.; Fox, K.; Mancini, F.; Canesi, M.; Odin, P.; Chaudhuri, K.R. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov. Disord., 2009, 24, 1468-1474.
112. Bové, J.; Prou, D.; Perier, C.; Przedborski, S. Toxin-induced models of Parkinson's disease. J. Am. Soc. Exp. Neurotherap., 2005, 2, 484-494.
113. Lima, M.M.S.; Braga Reksidler, A.; Marques Zanata, S.; Bueno Machado, H.; Tufik, S.; Vital, M.A. Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. Brain Res., 2006, 1101, 117-125.
114. Herrera, A.J.; Castano, A.; Venero, J.L.; Cano, J.; Machado, A. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol. Dis., 2000, 7, 429-447.
115. Ariza, D.; Lima, M.M.; Moreira, C.G.; Dombrowski, P.A.; Avila, T.V.; Allemand, A.; Mendes, D.A.; Da Cunha, C.; Vital, M.A. Intranigral LPS administration produces dopamine, glutathione but not behavioral impairment in comparison to MPTP and 6-OHDA neurotoxin models of Parkinson's disease. Neurochem. Res., 2010, 35, 1620-1627.
116. Delattre, A.M.; Kiss, A.; Szawka, R.E.; Anselmo-Franci, J.A.; Bagatini, P.B.; Xavier, L.L.; Rigon, P.; Achaval, M.; Iagher, F.; De David, C.; Marroni, N.A.; Ferraz, A.C. Evaluation of chronic omega-3 fatty acids supplementation on behavioral and neurochemical alterations in 6-hydroxydopamine-lesion model of Parkinson's disease. Neurosci. Res., 2010, 66, 256-264.
117. Cohen, G. Oxy-radical toxicity in catecholamine neurons. Neurotoxicology, 1984, 5, 77-82.
118. Glinka, Y.Y.; Youdim, M.B. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur. J. Pharmacol., 1995, 292, 329-332.
119. Truong, L.; Allbutt, H.; Kassiou, M.; Henderson, J.M. Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions. Behav. Brain Res., 2006, 169, 1-9.
120. Ferro, M.M.; Bellissimo, M.I.; Anselmo-Franci, J.A.; Angellucci, M.E.; Canteras, N.S.; Da Cunha, C. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J. Neurosci. Methods, 2005, 148, 78-87.
121. Monville, C.; Torres, E.M.; Dunnett, S.B. Validation of the l-dopainduced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. Brain Res Bull., 2005, 68, 16-23.
122. Sauer, H.; Oertel, W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience, 1994, 59, 401-415.
123. Mulcahy, P.; Walsh, S.; Paucard, A.; Rea, K.; Dowd, E. Characterisation of a novel model of Parkinson's disease by intrastriatal infusion of the pesticide rotenone. Neuroscience, 2011, 181, 234-242.
124. Tadaiesky, M.T.; Dombrowski, P.A.; Da Cunha, C.; Takahashi, R.N. Effects of SR141716A on cognitive and depression-related behavior in an animal model of premotor parkinson's disease. Parkinsons Dis., 2010, 2010, 1-6.
125. Pienaar, I.S.; Gotz, J.; Feany, M.B. Parkinson's disease: insights from non-traditional model organisms. Prog. Neurobiol., 2010, 92, 558-571.
126. +) in the brain of embryo and newborn mice. Exp. Toxicol. Pathol., 2011, in press.
127. Samadi, P.; Gregoire, L.; Rouillard, C.; Bedard, P.J.; Di Paolo, T.; Levesque, D. Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann. Neurol., 2006, 59, 282-288.
128. Przedborski, S.; Vila, M. MPTP: a review of its mechanisms of neurotoxicity. Clin. Neurosci. Res., 2001, 407-418.
129. Dauer, W.; Przedborski, S. Parkinson's disease: mechanisms and models. Neuron, 2003, 39, 889-909.
130. Emborg, M.E. Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J. Neurosci. Methods, 2004, 139, 121-143.
131. Reksidler, A.B.; Lima, M.M.; Dombrowski, P.; Andersen, M.L.; Zanata, S.M.; Andreatini, R.; Tufik, S.; Vital, M.A. Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease. J. Neurosci. Methods, 2008, 167, 268-277.
132. Goldberg, N.R.; Meshul, C.K. Effect of intermittent washout periods on progressive lesioning of the nigrostriatal pathway with 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuroscience, 2011, 182, 203-207.
133. Bousquet, M.; Gibrat, C.; Saint-Pierre, M.; Julien, C.; Calon, F.; Cicchetti, F. Modulation of brain-derived neurotrophic factor as a potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33, 1401-1408.
134. Cannon, J.R.; Tapias, V.; Na, H.M.; Honick, A.S.; Drolet, R.E.; Greenamyre, J.T. A highly reproducible rotenone model of Parkinson's disease. Neurobiol. Dis., 2009, 34, 279-290.
135. Moreira, C.G.; Barbiero, J.K.; Ariza, D.; Dombrowski, P.A.; Sabioni, P.; Bortolanza, M.; Cunha, C.D.; Vital, M.A.; Lima, M.M. Behavioral, neurochemical and histological alterations promoted by bilateral intranigral rotenone administration: a new approach for an old neurotoxin. Neurotox Res., 2012, 21(3), 291-301.
136. Inden, M.; Kitamura, Y.; Takeuchi, H.; Yanagida, T.; Takata, K.; Kobayashi, Y.; Taniguchi, T.; Yoshimoto, K.; Kaneko, M.; Okuma, Y.; Taira, T.; Ariga, H.; Shimohama, S. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J. Neurochem., 2007, 101, 1491-1504.
137. Pal, P.K.; Thennarasu, K.; Fleming, J.; Schulzer, M.; Brown, T.; Calne, S.M. Nocturnal sleep disturbances and daytime dysfunction in patients with Parkinson's disease and in their caregivers. Parkinsonism Relat. Disord., 2004, 10, 157-168.
138. Lapointe, N.; St-Hilaire, M.; Martinoli, M.G.; Blanchet, J.; Gould, P.; Rouillard, C.; Cicchetti, F. Rotenone induces non-specific central nervous system and systemic toxicity. FASEB J., 2004, 18, 717-719.
139. Antkiewicz-Michaluk, L.; Wardas, J.; Michaluk, J.; Romaska, I.; Bojarski, A.; Vetulani, J. Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. Int. J. Neuropsychopharmacol., 2004, 7, 155-163.
140. Kamat, C.D.; Gadal, S.; Mhatre, M.; Williamson, K.S.; Pye, Q.N.; Hensley, K. Antioxidants in Central nervous system diseases: preclinical promise and translational challenges. J. Alzheimers Dis., 2008, 15, 473-493.
141. Kitamura, Y.; Taniguchi, T.; Ariga, H. Translational research of parkinsonian therapeutics. Yakugaku Zasshi J. Pharm. Soc. Jpn., 2008, 128, 53-56.
142. Bjorklund, A.; Cenci, M.A. Recent advances in Parkinson's disease: translational and clinical research preface. In: A. Bjorklund and M.A. Cenci (Eds.), Recent Advances in Parkinsons Disease: Translational and Clinical Research, Vol. 184, Elsevier Science Bv, Amsterdam, 2010, pp. 7-8.
143. Ciucci, M.R.; Vinney, L.; Wahoske, E.J.; Connor, N.P. A translational approach to vocalization deficits and neural recovery after behavioral treatment in Parkinson disease. J. Commun. Disord., 2010, 43, 319-326.
144. Antony, P.M.A.; Diederich, N.J.; Balling, R. Parkinson's disease mouse models in translational research. Mamm. Genome, 2011, 22, 401-419.
145. Klein, C.; Krainc, D.; Schlossmacher, M.G.; Lang, A.E. Translational Research in Neurology and Neuroscience 2011. Arch. Neurol., 2011, 68, 709-716.
146. Neuwelt, E.A.; Bauer, B.; Fahlke, C.; Fricker, G.; Iadecola, C.; Janigro, D.; Leybaert, L.; Molnar, Z.; O'donnell, M.E.; Povlishock, J.T.; Saunders, N.R.; Sharp, F.; Stanimirovic, D.; Watts, R.J.; Drewes, L.R. Engaging neuroscience to advance translational research in brain barrier biology. Nat. Rev. Neurosci., 2011, 12, 169-182.
147. Andersen, J.K. Arvid Carlsson: An Early Pioneer in Translational Medicine. Sci. Transl. Med., 2009, 1(2), 2ps3.